<cite id="5nld9"><span id="5nld9"><ol id="5nld9"></ol></span></cite>

    <big id="5nld9"></big>

      <noframes id="5nld9">
      <big id="5nld9"><form id="5nld9"><nobr id="5nld9"></nobr></form></big>

      <address id="5nld9"><video id="5nld9"></video></address>
      <progress id="5nld9"></progress>

        English 中文簡體 中文繁體

        Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting portfolio of pipelines with clear differentiation and global competitiveness. With clinically proven targets, CMC-validated manufacturing and global IP rights, Alphamab Oncology has created well-rounded pipeline projects with low risk and superb upside potential.

        Recent progress in cancer immunotherapy has marked a historic breakthrough. At Alphamab Oncology, we have developed not only a well differentiated PD-L1 antibody (KN035), but also a potential backbone of next generation immuno-oncology therapy (KN046), representing a leap forward from currently available drugs on the market or in development.

        Several other bispecific programs with best-in-class or first-in-class potential are also under development.

        Pipeline Programs